The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 87)
Research Grant, 2018
Mutations (changes) in the gene for the leucine-rich repeat kinase 2 (LRRK2) protein cause inherited Parkinson's disease (PD). Because the activity of LRRK2 is increased in such mutant proteins, drugs have been designed to reduce this activity with the intention of curing PD. However, it is unclear whether these drugs are safe for people because side effects have been observed in p...
Researchers: Elisa Greggio, PhD
Target Advancement Program, 2018
Hexosaminidase (HEX) is a protein that is stored inside lysosomes, tiny bubbles inside the cell responsible for getting rid of its waste. A lack of HEX is associated with Sandhoff disease, in which fatty substances build up in the body. Studying pre-clinical models of Sandhoff disease, we noticed hallmarks of Parkinson's disease (PD): an increase in alpha-synuclein clumps and a lo...
Researchers: Ole Isacson, MD, PhD
Therapeutic Pipeline Program, 2018
Gene therapy is one of the most promising tools for the treatment of Parkinson's disease (PD). We have developed a novel system to treat brain diseases using exosomes, which are small sacs of cellular material released by a cell. We modified exosomes to target the brain after injection into the blood stream, and we developed ways to insert into the exosome small hairpin RNA (shRNA...
Researchers: Lydia Alvarez-Erviti, PhD
Research Grant, 2017
Parkinson's disease (PD) is characterized by impairment of motor control as a result from extensive neuron death. The primary mechanism responsible for the progressive neuronal loss in PD remains unknown; however, clues have been obtained from families who have a genetic form of PD that is accompanied by a mutation (change in genetic material, or DNA) in an important protein called...
Researchers: Claudio Hetz Flores, PhD
Target Validation, 2015
Lysosomes are key intra-cellular organelles involved in the degradation of proteins including alpha-synuclein. Lysosomal protein degradation systems fail in Parkinson's disease (PD). Nedd4 and glucocerebrosidase (GBA) are two important targets involved in the clearance of alpha-synuclein through lysosomal pathways. We have previously shown that overexpression of ...
Researchers: Penelope Hallett, PhD